Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma
Rajappa S. Kenchappa(Mayo Clinic in Florida), Steven S. Rosenfeld(WinnMed), Lauren Stopfer(Io Therapeutics (United States)), Athanassios Dovas(Columbia University Irving Medical Center), Natanael Zarco(Mayo Clinic in Florida), Christian T. Meyer(Vanderbilt University), Brianna Pereira(Columbia University Irving Medical Center), Ashley Haddock(Mayo Clinic in Florida), William F. Elmquist(University of Minnesota), Surabhi Talele(University of Minnesota), Peter Canoll(Columbia University Irving Medical Center), Afroz S. Mohammad(University of Minnesota), Matei A. Banu(Stanford Medicine), Peter A. Sims(Columbia University Irving Medical Center), Michael Argenziano(Royal College of Physicians), Forest M. White(Center for Cancer Research), Jessica I. Griffith(University of Minnesota), Vito Quaranta(Northeastern University)
Cited by 31
Related Papers
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease
|Nature Communications|2019|814